⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for 6mhp

Every month we try and update this database with for 6mhp cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of MelanomaNCT02425306
Melanoma
6MHP
Montanide ISA-5...
polyICLC
Cyclophosphamid...
18 Years - University of Virginia
Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of MelanomaNCT02425306
Melanoma
6MHP
Montanide ISA-5...
polyICLC
Cyclophosphamid...
18 Years - University of Virginia
A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With MelanomaNCT02385669
Melanoma
Ipilimumab
6MHP
18 Years - University of Virginia
A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and TrametinibNCT02382549
Melanoma
BRAF inhibitor
6MHP
MEK inhibitor
18 Years - University of Virginia
A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and TrametinibNCT02382549
Melanoma
BRAF inhibitor
6MHP
MEK inhibitor
18 Years - University of Virginia
Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV MelanomaNCT03617328
Melanoma
6MHP
Montanide ISA-5...
polyICLC
CDX-1127
18 Years - University of Virginia
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)NCT04364230
Melanoma
Ocular Melanoma
Uveal Melanoma
6MHP
NeoAg-mBRAF
PolyICLC
CDX-1140
18 Years - University of Virginia
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)NCT04364230
Melanoma
Ocular Melanoma
Uveal Melanoma
6MHP
NeoAg-mBRAF
PolyICLC
CDX-1140
18 Years - University of Virginia
Safety Study of a Helper Peptide Vaccine Plus PembrolizumabNCT02515227
Melanoma
6MHP
Pembrolizumab
18 Years - University of Virginia
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: